This page shows the latest Roivant news and features for those working in and with pharma, biotech and healthcare.
Pfizer and Roivant Sciences have launched a new company focused on developing RVT-3101, a fully human monoclonal antibody targeting TL1A, for inflammatory and fibrotic diseases. ... Mayukh Sukhatme, president and chief investment officer of Roivant, said:
companies in the Roivant Sciences group headed by entrepreneur Vivek Ramaswamy – in September.
The five companies Sumitomo is set to take over from Roivant include Myovant, Urovant, Enzyvant, Altavant and another undisclosed spinout company. ... in this alliance,” said Vivek Ramaswamy, founder and chief executive officer of Roivant.
The company, part of the Swiss Roivant group headed by Vivek Ramaswamy, says the LIBERTY 2 trial showed a 71.2% response rate for once-daily relugolix in women with uterine
Roivant Sciences subsidiary Metavant licensed US and European rights to the drug last year for $35m upfront, a $15m equity investment and up to $500m in milestone payments.
The company, part of the Swiss Roivant group headed by Vivek Ramaswamy, reported that 73% of women with uterine fibroids and heavy menstrual bleeding who were treated with relugolix responded to
More from news
Approximately 8 fully matching, plus 11 partially matching documents found.
110. Arena Pharmaceuticals/ Roivant Sciences. Licence agreement. For Nelotanserin a 5-HT2A receptor P2 in behavioural and neuropsychiatric disturbances.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
I am also eager to leverage the Roivant platform to accelerate the development of Axovant’s pipeline.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...